Compare Becton Dickinson and Co (BDX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Novo Nordisk A/S — how do they compare? Becton Dickinson and Co trades at $179.02 (market cap $49.41B), while Novo Nordisk A/S trades at $46.13 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 4.2× Becton Dickinson and Co's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| BDX | NVO | |
|---|---|---|
Market Cap | $49.41B | $207.85B |
Sector | Health | Health |
52-Week High | $185.39 | $63.98 |
52-Week Low | $138.62 | $35.29 |
Enterprise Value | $65.51B | $222.55B |
Dividend Yield | 2.32% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
